Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making
Molecular Imaging and Radionuclide Therapy · 01.02.2017 · 26 (1(1)) · 36-49
DOI: 10.4274/2017.26.suppl.05 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Imaging and Radionuclide Therapy, erschienen am 01.02.2017. Verfasst von Richard T Kloos. Beteiligte Einrichtung: Veracyte, Inc., Department of Medical Affairs, Senior Medical Director-Endocrinology, California, USA, Phone: +1(650)243-6300, E-mail: richard.kloos@…. Die Arbeit wurde bisher 43-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Veracyte, Inc., Department of Medical Affairs, Senior Medical Director-Endocrinology, California, USA, Phone: +1(650)243-6300, E-mail: richard.kloos@veracyte.com.
Zitieren
APA
Kloos, R. T. (2017). Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making. Molecular Imaging and Radionuclide Therapy, 26(1(1)), 36-49. https://doi.org/10.4274/2017.26.suppl.05
Vancouver
Kloos RT. Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making. Molecular Imaging and Radionuclide Therapy. 2017;26(1(1)):36-49. doi:10.4274/2017.26.suppl.05
BibTeX
@article{Kloos2017,
author = {Kloos, Richard T},
title = {Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making},
journal = {Molecular Imaging and Radionuclide Therapy},
year = {2017},
volume = {26},
number = {1(1)},
pages = {36--49},
doi = {10.4274/2017.26.suppl.05}
}
EUVIMED